Does Rallies show 13F holders for DGX?

Yes. Rallies tracks hedge fund and 13F ownership data for DGX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DGX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DGX. It does not provide personalized investment advice.

DGX (Quest Diagnostics Inc.) Stock Analysis - Hedge Fund Holdings

Quest Diagnostics Inc. (DGX) is a publicly traded Healthcare sector company. As of May 21, 2026, DGX trades at $193.75 with a market cap of $21.01B and a P/E ratio of 21.18. DGX moved +2.02% today. Year to date, DGX is +11.68%; over the trailing twelve months it is +8.70%. Its 52-week range spans $146.17 to $213.50. Analyst consensus is buy with an average price target of $220.50. Rallies surfaces DGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DGX stock?

Hedge funds tracked by Rallies that own DGX include Redmile Group, Pinebridge Investments, Panagora Asset, Bridgewater Associates, and Maverick Capital. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Quest Diagnostics Inc..

DGX Key Metrics

Key financial metrics for DGX
Metric	Value
Price	$193.75
Market Cap	$21.01B
P/E Ratio	21.18
EPS	$9.17
Dividend Yield	0.86%
52-Week High	$213.50
52-Week Low	$146.17
Volume	0
Avg Volume	0
Revenue (TTM)	$11.28B
Net Income	$1.07B
Gross Margin	33.20%

Top Hedge Funds Holding DGX

Redmile Group holds 83.85K shares of DGX, changed +0.00% as of Mar 31, 2024.
Pinebridge Investments holds 22.80K shares of DGX, changed +258.79% as of Mar 31, 2024.
Panagora Asset holds 4.19K shares of DGX, changed +151.98% as of Mar 31, 2026.
Bridgewater Associates holds 3.47K shares of DGX, changed -1.34% as of Mar 31, 2026.
Maverick Capital holds 2.76K shares of DGX, changed -88.47% as of Mar 31, 2026.

Latest DGX News

Quest Diagnostics jumps after Q1 beat and raised 2026 revenue, EPS guidance — Apr 30, 2026
Quest Diagnostics drops as CMS “CRUSH” policy overhang hits lab-testing stocks — Apr 29, 2026
Quest Diagnostics Prices $500 M 5.00% Senior Notes Due 2036 — Apr 27, 2026
Quest Diagnostics slides as post-earnings profit-taking hits shares after raised 2026 outlook — Apr 23, 2026
Quest Diagnostics jumps after Q1 2026 beat and higher full-year guidance — Apr 21, 2026

Recent DGX Insider Trades

Doherty Catherine T. sold 5.56K (~$1.15M) on Mar 5, 2026.
PREVOZNIK MICHAEL E sold 3.88K (~$799.68K) on Mar 5, 2026.
Plewman Patrick sold 2.85K (~$588.73K) on Mar 5, 2026.

DGX Analyst Consensus

9 analysts cover DGX: 0 strong buy, 4 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $220.50.

Common questions about DGX

Who owns DGX stock?: Hedge funds tracked by Rallies that own DGX include Redmile Group, Pinebridge Investments, Panagora Asset, Bridgewater Associates, and Maverick Capital. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Quest Diagnostics Inc..
Does Rallies show 13F holders for DGX?: Yes. Rallies tracks hedge fund and 13F ownership data for DGX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DGX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DGX. It does not provide personalized investment advice.